Sign in
Not yet recruitingPhase 2/3

Memantine as an Additive Therapy in Patients With Traumatic Brain Injury

Key facts

Who runs it
Mansoura University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 2/3
People taking part
80 people, planned
Started
25 Mar 2025
Planned end
30 Nov 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Memantine
  • Mannitol
Record updated
6 April 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Patients between 18 and 70 years of age
  • Patients mild (GCS 13-15) to moderate (GCS 9-12) TBI were assessed for the study eligibility

Who cannot take part

  • Comorbid illnesses, such as diabetes mellitus, ischemic heart disease, acute myocardial infarction within the past 48 hours
  • Acute or chronic renal insufficiency
  • Hepatic diseases
  • Autoimmune diseases
  • Malignancies
  • Pregnancy
  • Patients unable to tolerate enteral feeding
  • More than 24 hours (h) since traumatic injury

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Memantine has shown promise in mitigating secondary brain injury in previous studies. One study demonstrated that early memantine administration in moderate TBI patients resulted in lower serum neuron-specific enolase levels and improved Glasgow Coma Scale scores. However, other trials investigating memantine's impact on long-term cognitive function in TBI patients have yielded mixed results. There is a need for well-controlled studies to determine the efficacy of memantine in improving neurological and cognitive outcomes in patients with TBI.

The 2 groups in the trial

  • Memantine groupExisting treatment, for comparison

    Mild to moderate TBI patients will receive memantine. It will be given either orally or through a nasogastric tube for 7 days, starting on the first day of admission to the hospital and then continued for 3 weeks. The memantine dose in the first 7 days is 30 mg twice daily, while during the remaining 3 weeks the dose is 10 mg twice daily

    Treatment: Memantine

  • Control groupOther group

    Mild to moderate TBI patients will be managed by mannitol or hypertonic saline to reduce brain swelling and analgesic for headache such as; acetaminophen.

    Treatment: Mannitol

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
6 April 2025